RR-11a

• Description:

  RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM) . RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) [1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Legumain

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/RR-11a.html

• Concentration:

  10mM

• Purity:

  98.08

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](C)C(N[C@@H](C)C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)=O)OCC2=CC=CC=C2

• Molecular Formula:

  C24H28N6O10

• Molecular Weight:

  560.51

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7 (6) :665-73.|[2]Ralph A, et al. Nanoparticle-based tumor-targeted drug delivery. Patent: CA2809617C|[3]Yang H, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11 (11) :1014. Published 2020 Nov 26.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1361390-56-8]